Home Cart Sign in  
Chemical Structure| 76963-41-2 Chemical Structure| 76963-41-2

Structure of Nizatidine
CAS No.: 76963-41-2

Chemical Structure| 76963-41-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nizatidine is an antagonist of histamine H2 receptor that can inhibit the secretion of gastric acid.

Synonyms: LY139037

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nizatidine

CAS No. :76963-41-2
Formula : C12H21N5O2S2
M.W : 331.46
SMILES Code : O=[N+](/C=C(NCCSCC1=CSC(CN(C)C)=N1)\NC)[O-]
Synonyms :
LY139037
MDL No. :MFCD00865660
InChI Key :SGXXNSQHWDMGGP-IZZDOVSWSA-N
Pubchem ID :3033637

Safety of Nizatidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Nizatidine

GPCR

Isoform Comparison

Biological Activity

Target
  • H2 receptor

    Histamine H2 receptor, IC50:0.9 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Huh7.5.1dif cells 10 µM 48 hours Reversed the HCV-induced poor-prognosis PLS status PMC8448834
THP1-derived macrophages 20 µM 48 hours Decreased pro-inflammatory cytokine expression PMC8448834
Rat erythrocytes 1.4×10^-6M To determine the inhibitory activity of nizatidine on acetylcholinesterase (AChE) PMC4688838
HuH-7 10 μM 48 hours Nizatidine downregulated cccDNA levels PMC10604930
Caco-2 cells 0.05–10 mM 120 minutes To investigate the intestinal epithelial cell efflux transport mechanisms of nizatidine, it was found that nizatidine exhibited 7.7-fold higher BL–AP than AP–BL Caco-2 permeability, indicative of net mucosal secretion. All P-gp inhibitors displayed concentration-dependent inhibition. PMC2691456
Caco-2 cells 3.13, 6.25, 12.5 μg/mL 24 hours To evaluate the biocompatibility of nanofibers and the removal of unreacted glutaraldehyde. Results showed that the viability of Caco-2 cells was 86.87 ± 6.86%, indicating good biocompatibility of the nanofibers. PMC8428272
RAW264.7 cell line 6 μg/ml 48 hours To evaluate the effect of Nizatidine on APC activation, results showed upregulated expression levels of MHC II, CD40, and CD80 PMC4185914
DC2.4 cell line 6 μg/ml 48 hours To evaluate the effect of Nizatidine on APC activation, results showed increased expression levels of MHC II and CD40 PMC4185914
RAW264.7 cell line 6 μg/ml 48 hours To evaluate the effect of Nizatidine on APC activation, results showed upregulation of MHC II, CD40, and CD80 PMC4185914
DC2.4 cell line 6 μg/ml 48 hours To evaluate the effect of Nizatidine on APC activation, results showed increased levels of MHC II and CD40 PMC4185914

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rat DEN-induced fibrosis and HCC model Oral gavage 15 mg/kg Daily for 9 weeks Reduced liver fibrosis and HCC development PMC8448834
Rats Ethanol-induced gastric injury model Oral 30 mg/kg 5 consecutive days To evaluate the gastroprotective effect of nizatidine nanofibers against ethanol-induced gastric injury. Results showed that crosslinked nanofibers significantly enhanced the gastroprotective activity of nizatidine and preserved the gastric wall architecture, COX-2 expression, and oxidative stress markers levels of the normal rats. PMC8428272
Rats Duodenal HCO3- secretion model Intravenous injection 3-30mg/kg Single dose, observed for 2 hours To investigate the stimulatory effect of nizatidine on duodenal HCO3- secretion in rats and its mechanism PMC4688838
C57BL/6 mice H5N1 killed viral antigen immunization model Intramuscular injection 0.62 mg/mice Single immunization To evaluate the adjuvant effect of Nizatidine on H5N1 vaccine, results showed significant improvement in animal survival and reduction in viral loads in lung tissues PMC4185914

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03509831 Gastritis Phase 1 Active, not recruiting April 2018 Korea, Republic of ... More >> Kukje Pharm Seongnam-si, Korea, Republic of Less <<
NCT02555852 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02703896 Pulmonary Aspiration of Gastri... More >>c Contents Less << Phase 4 Completed - -
NCT02951715 Hearing Loss, Noise-Induced ... More >> Tinnitus, Noise Induced Zinc Deficiency Less << Not Applicable Completed - -
NCT00486005 Schizophrenia Phase 4 Completed - Brazil ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician Rio de Janeiro, Brazil Less <<
NCT00373334 Gastroesophageal Reflux Diseas... More >>e GERD Heartburn Less << Phase 3 Completed - -
NCT01161927 Healthy Phase 1 Completed - -
NCT02232308 Gastroparesis Phase 1 Completed - United States, Minnesota ... More >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01161940 Healthy Phase 1 Completed - -
NCT00373334 - Completed - -
NCT01409395 Healthy Phase 1 Completed - United States, California ... More >> Ucsf Ctsi Crc San Francisco, California, United States, 94158 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.02mL

0.60mL

0.30mL

15.08mL

3.02mL

1.51mL

30.17mL

6.03mL

3.02mL

References

 

Historical Records

Categories